<code id='F83AB0E2B6'></code><style id='F83AB0E2B6'></style>
    • <acronym id='F83AB0E2B6'></acronym>
      <center id='F83AB0E2B6'><center id='F83AB0E2B6'><tfoot id='F83AB0E2B6'></tfoot></center><abbr id='F83AB0E2B6'><dir id='F83AB0E2B6'><tfoot id='F83AB0E2B6'></tfoot><noframes id='F83AB0E2B6'>

    • <optgroup id='F83AB0E2B6'><strike id='F83AB0E2B6'><sup id='F83AB0E2B6'></sup></strike><code id='F83AB0E2B6'></code></optgroup>
        1. <b id='F83AB0E2B6'><label id='F83AB0E2B6'><select id='F83AB0E2B6'><dt id='F83AB0E2B6'><span id='F83AB0E2B6'></span></dt></select></label></b><u id='F83AB0E2B6'></u>
          <i id='F83AB0E2B6'><strike id='F83AB0E2B6'><tt id='F83AB0E2B6'><pre id='F83AB0E2B6'></pre></tt></strike></i>

          knowledge

          knowledge

          author:fashion    Page View:5
          Stock exchange
          Drew Angerer/Getty Images

          Viking Therapeutics said Tuesday that its closely watched oral obesity drug had succeeded in an early-stage trial and that it planned to advance the medicine into the next phase of development. 

          The top-line results released Tuesday were only from a Phase 1 study, which primarily focuses on a drug’s safety. But Viking said that in the study, its medicine led to a roughly 3.3% placebo-adjusted average weight loss after four weeks and that it showed no safety issues.

          advertisement

          In preview notes, analysts had said that investors would want to see between 3% and 4% placebo-adjusted weight loss. Shares of San Diego-based Viking were up more than 20% in pre-market trading Tuesday.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more
          FDA approves potent Eli Lilly obesity drug, Zepbound
          FDA approves potent Eli Lilly obesity drug, Zepbound

          DarronCummings/APEliLilly’sblockbusterdrugtirzepatide,soldasMounjarofortype2diabetes,hasbeenclearedt

          read more
          Virginia high school admissions case could be legal follow
          Virginia high school admissions case could be legal follow

          3:24DemonstratorsprotestoutsideoftheSupremeCourtinWashington,Thursday,June29,2023,aftertheSupremeCou

          read more

          A clever new way to fix Medicaid and graduate medical education

          AdobeLately,we’veseentwodistinctlinesatourhospitals.Wewouldallbehealthierifwebroughtthetwolinestoget